Agenus opened lower at $6.87, compared with its previous close of $7.09. In the last trading session, the stock traded between $6.69 and $7.09. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Agenus is now worth
$ 8.73
resulting in a loss of
$ 91.27 (91.27%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.39 (-5.43%)
Day High
$7.09
Day Low
$6.69
Day Open
$6.87
Prev Close
$7.09
Volume
2,01,921
1W Return
2.95%
1M Return
-32.17%
3M Return
1.09%
6M Return
74.61%
1Y Return
74.16%
Market Cap ($ Mn)
303
PE Ratio
3.03
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-128.86%
EPS (TTM)
$0.92
1 Week
2.95%
1 Month
-32.17%
3 Months
1.09%
6 Months
74.61%
9 Months
124.25%
Agenus: 25% of ovarian cancer patients alive off therapy in trial
25% of recurrent ovarian cancer patients were alive and off all therapy at last follow-up. Estimated three-year survival rate reached 48% among evaluable patients. Study included heavily pretreated patients with a median of four prior lines of therapy. Nearly 75% of participants had platinum-resistant or refractory ovarian cancer.
25 days agoAgenus to present botensilimab research at SITC 2026 annual meeting
Agenus Inc. will present two posters on botensilimab and balstilimab at SITC 2026 in Phoenix. One poster reviews long-term survivors of refractory microsatellite-stable metastatic colorectal cancer. Second poster covers preclinical research combining these antibodies with MiNK Therapeutics’ agenT-797. Event dates are November 4-8, 2026.
28 days agoAgenus executives to speak at September investor conferences
Agenus Inc. executives to speak at Cantor and H.C. Wainwright conferences in September 2026. Fireside chats scheduled for September 8 and September 14 in New York. Robin Taylor and Zack Armen will lead investor discussions on immuno-oncology pipeline. Recordings available for 90 days post-event on company investor site.
2mo agoAgenus publishes Phase 1b data showing 21.2-month median survival for MSS mCRC
Agenus published mature Phase 1b data for botensilimab plus balstilimab in Clinical Cancer Research. Median overall survival reached 21.2 months with a 33% three-year survival rate in 123 patients. Confirmed objective response rate was 21% across the cohort. No new safety signals emerged during extended follow-up.
2mo agoAgenus NEST trial shows no colorectal cancer recurrences at 32 months
No colorectal cancer recurrences observed at median follow-up of 32.2 months in NEST-1. Neoadjuvant BOT+BAL achieved 59% pathologic response rate in pMMR/MSS tumors. 88% of evaluable patients cleared ctDNA before surgery with no procedural delays. Results support advancement of global Phase 3 ROBBIN trial in MSS colon cancer.
2mo agoCheckpoint inhibitor refractory cancer market to grow by 2036
DelveInsight forecasts growth in the checkpoint inhibitor refractory cancer market through 2036, driven by high resistance rates (40–60%) and novel pipeline candidates. The US leads the 7MM market size as of 2025, with Agenus reporting a 77% disease control rate in recent Phase II data.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Agenus is now worth
$ 8.73
resulting in a loss of
$ 91.27 (91.27%)
Note: Past profits do not guarantee future returns.
